Article
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Cancer - 1 Feb 2015
Villaruz Liza C, Socinski Mark A, Abberbock Shira, Berry Lynne D, Johnson Bruce E, Kwiatkowski David J, Iafrate A John, Varella-Garcia Marileila, Franklin Wilbur A, Camidge D Ross, Sequist Lecia V, Haura Eric B, Ladanyi Mark, Kurland Brenda F, Kugler Kelly, Minna John D, Bunn Paul A, Kris Mark G
Abstract excerpt
BACKGROUND: The advent of effective targeted therapy for BRAF(V600E) -mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth...
Topics
- Adenocarcinoma
- Adenocarcinoma of Lung
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Class I Phosphatidylinositol 3-Kinases
- Cohort Studies
- ErbB Receptors